RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to hold an Investor and Analyst Day on Friday, September 20, from 9:00 a.m. to 12:00 p.m. Eastern Time. This event will take place in New York and be accessible via webcast.
The focus will be on Marinus’s development program for ZTALMY® (ganaxolone) oral suspension CV, specifically targeting tuberous sclerosis complex (TSC). This comes as the company anticipates the Phase 3 TrustTSC trial data readout in the early fourth quarter of 2024.
Key presentations will come from Marinus management and expert opinion leaders. The event is open in-person to invited research analysts and institutional investors, while others can join through the webcast. Attendees can engage by submitting questions during the event.
Marinus, known for its innovative therapies for seizure disorders, launched ZTALMY® in the U.S. in 2022. This Investor and Analyst Day provides a platform to update stakeholders on the progress and potential of its key therapeutic developments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.